Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases.

Autor: Kahraman S; Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara Yildirim Beyazit University, 06800, Ankara, Turkey. sedakayacan.kahraman@gmail.com., Karakaya S; Department of Medical Oncology, Ankara Ataturk Sanatoryum Training and Research Hospital, Ankara, Turkey., Kaplan MA; Department of Medical Oncology, Dicle University Medical Faculty Hospital, Diyarbakir, Turkey., Goksu SS; Department of Medical Oncology, Akdeniz University Hospital, Antalya, Turkey., Ozturk A; Department of Medical Oncology, Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital, Istanbul, Turkey., Isleyen ZS; Department of Medical Oncology, Faculty of Medicine Hospital, Bezmialem Vakif University, Istanbul, Turkey., Hamdard J; Department of Medical Oncology, Medipol University Hospital, Istanbul, Turkey., Yildirim S; Department of Medical Oncology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkey., Dogan T; Department of Medical Oncology, Pamukkale University Medical Faculty Hospital, Denizli, Turkey., Isik S; Department of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul, Turkey., Celebi A; Department of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul, Turkey., Gulbagci BB; Department of Medical Oncology, Sakarya University School of Medicine, Sakarya, Turkey., Paksoy N; Department of Medical Oncology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey., Dogan M; Department of Medical Oncology, Ankara Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey., Turk HM; Department of Medical Oncology, Faculty of Medicine Hospital, Bezmialem Vakif University, Istanbul, Turkey., Bilici A; Department of Medical Oncology, Medipol University Hospital, Istanbul, Turkey., Tatli AM; Department of Medical Oncology, Akdeniz University Hospital, Antalya, Turkey., Akbas S; Department of Medical Oncology, Koç University Medical Faculty Hospital, Istanbul, Turkey., Turan N; Department of Medical Oncology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkey., Hacibekiroglu I; Department of Medical Oncology, Sakarya University School of Medicine, Sakarya, Turkey., Dogu GG; Department of Medical Oncology, Pamukkale University Medical Faculty Hospital, Denizli, Turkey., Aydiner A; Department of Medical Oncology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey., Sumbul AT; Department of Medical Oncology, Baskent University Adana Dr. Turgut Noyan Application and Research Center, Adana, Turkey., Akyurek S; Department of Radiation Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey., Yalciner M; Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey., Demirkazik A; Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey., Gursoy P; Department of Medical Oncology, Ege University Medical Faculty Hospital, Izmir, Turkey., Aykan MB; Department of Medical Oncology, Gulhane Training and Research Hospital, Ankara, Turkey., Sahin E; Department of Medical Oncology, Kocaeli University Medical Faculty Hospital, Kocaeli, Turkey., Karadag İ; Department of Medical Oncology, Hittite University Corum Training and Research Hospital, Corum, Turkey., Kostek O; Department of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul, Turkey., Er MM; Department Of Medical Oncology, Necmettin Erbakan University Meram Medical Faculty Hospital, Konya, Turkey., Artaç M; Department Of Medical Oncology, Necmettin Erbakan University Meram Medical Faculty Hospital, Konya, Turkey., Duzkopru Y; Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Turkey., Aydin D; Department of Medical Oncology, Kocaeli Derince Training and Research Hospital, Kocaeli, Turkey., Isik D; Department of Medical Oncology, Kocaeli Medical Park Hospital, Kocaeli, Turkey., Karakas Y; Department of Medical Oncology, Acıbadem Bodrum Hospital, Mugla, Turkey., Kilickap S; Department of Medical Oncology, Liv Hospital, Istinye University, Ankara, Turkey., Erol C; Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara Yildirim Beyazit University, 06800, Ankara, Turkey., Demir B; Department of Medical Oncology, Aydin Ataturk State Hospital, Aydin, Turkey., Civelek B; Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey., Ergun Y; Department of Medical Oncology, Batman Training and Research Hospital, Batman, Turkey., Akinci MB; Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara Yildirim Beyazit University, 06800, Ankara, Turkey., Dogan I; Department of Medical Oncology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey., Karadurmus N; Department of Medical Oncology, Gulhane Training and Research Hospital, Ankara, Turkey., Yumuk PF; Department of Medical Oncology, Koç University Medical Faculty Hospital, Istanbul, Turkey., Sendur MAN; Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara Yildirim Beyazit University, 06800, Ankara, Turkey.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2024 Mar 09; Vol. 14 (1), pp. 5820. Date of Electronic Publication: 2024 Mar 09.
DOI: 10.1038/s41598-024-56046-w
Abstrakt: Central nervous system (CNS) metastases can be seen at a rate of 30% in advanced stages for patients with non-small cell lung cancer (NSCLC). Growing evidence indicates the predictive roles of driver gene mutations in the development of brain metastases (BM) in recent years, meaning that oncogene-driven NSCLC have a high incidence of BM at diagnosis. Today, 3rd generation targeted drugs with high intracranial efficacy, which can cross the blood-brain barrier, have made a positive contribution to survival for these patients with an increased propensity to BM. It is important to update the clinical and pathological factors reflected in the survival with real-life data. A multi-center, retrospective database of 306 patients diagnosed with driver mutant NSCLC and initially presented with BM between between November 2008 and September 2022 were analyzed. The median progression-free survival (mPFS) was 12.25 months (95% CI, 10-14.5). While 254 of the patients received tyrosine kinase inhibitor (TKI), 51 patients received chemotherapy as first line treatment. The median intracranial PFS (iPFS) was 18.5 months (95% CI, 14.8-22.2). The median overall survival (OS) was 29 months (95% CI, 25.2-33.0). It was found that having 3 or less BM and absence of extracranial metastases were significantly associated with better mOS and iPFS. The relationship between the size of BM and survival was found to be non-significant. Among patients with advanced NSCLC with de novo BM carrying a driver mutation, long-term progression-free and overall survival can be achieved with the advent of targeted agents with high CNS efficacy with more conservative and localized radiotherapy modalities.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje